---
title: "Control-arm mismatches in NCI multiple myeloma randomized trials"
id: "nature-reviews-clinical-oncology-0-problematic-control-arms-in-national-cancer-institute-myeloma-trials"
canonical_url: "https://medichelpline.com/clinical-feed/nature-reviews-clinical-oncology-0-problematic-control-arms-in-national-cancer-institute-myeloma-trials"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "Nature Reviews Clinical Oncology"
source_url: "https://www.nature.com/articles/s41571-026-01221-3"
published_at: "2026-10-28T12:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Control-arm mismatches in NCI multiple myeloma randomized trials
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/nature-reviews-clinical-oncology-0-problematic-control-arms-in-national-cancer-institute-myeloma-trials
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** Nature Reviews Clinical Oncology
- **Source URL:** [Original Journal Publication](https://www.nature.com/articles/s41571-026-01221-3)
- **Published At:** 2026-10-28T12:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- Investigators reported that, among five National Cancer Institute (NCI)-sponsored randomized trials currently enrolling patients with **multiple myeloma**, three use control arms that no longer reflect contemporary standard-of-care practice. - Two of the three trials with problematic comparators were activated in 2026, the authors noted, indicating recent trial starts nonetheless use outdated comparators. - The study team argued that federally sponsored trial comparators require reassessment and potential amendment to align with changes in clinical practice both before and during enrolment. - Data used for the analysis derive from publicly accessible records on ClinicalTrials.gov; the authors state the study dataset and analysis criteria are available on request by e-mail to the corresponding author. - The article references contemporary myeloma practice evidence, including phase 3 and guideline publications that establish daratumumab-containing regimens and recent NCCN guidance updates. - Authors and affiliations are listed: Jacqueline Kunesh (University of Arizona College of Medicine–Phoenix) and Ghulam Rehman Mohyuddin (Division of Hematology and Hematological Malignancies, The University of Utah). - Competing-interest disclosure: G.R.M.’s institution has received research funding from Janssen and Sanofi; J.K. declared no competing interests. - The authors recommended that federally sponsored trials update comparators as practice evolves; they called for reassessment processes to occur before and during patient enrolment to maintain ethical and scientific validity. - The article acknowledges that all analyzed data are publicly available; the authors offered the study dataset upon request and cited prior systematic reviews and recent randomized trials and guideline updates relevant to myeloma care. - The commentary signals broader concerns about control-arm adequacy in oncology trials and refers readers to earlier meta-research and recent myeloma trials that influence standard practice.
## Clinical Analysis & Structured Key Points
## Your privacy, your choice We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media, as well as to allow video information to be shared for both marketing, analytics and editorial purposes. By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection. See our [privacy policy](https://www.nature.com/info/privacy) for more information on the use of your personal data. Manage preferences for further information and to change your choices. Accept all cookies Reject optional cookies [Skip to main content](https://www.nature.com/articles/s41571-026-01221-3#content) Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript. Advertisement [ ![Nature Reviews Clinical Oncology](https://media.springernature.com/full/nature-cms/uploads/product/nrclinonc/header-6cacb5c22900eb4634682a8eae5b788c.svg) ](https://www.nature.com/nrclinonc) * [ View all journals ](https://www.nature.com/siteindex) * [ Saved research ](https://www.nature.com/saved-research) * [ Search ](javascript:;) ## Search Search articles by subject, keyword or author Show results from All journals This journal Search [ Advanced search ](https://www.nature.com/search/advanced) ### Quick links * [Explore articles by subject](https://www.nature.com/subjects) * [Find a job](https://www.nature.com/naturecareers) * [Guide to authors](https://www.nature.com/authors/index.html) * [Editorial policies](https://www.nature.com/authors/editorial_policies/) * [Log in](https://idp.nature.com/auth/personal/springernature?redirect_uri=https://www.nature.com/articles/s41571-026-01221-3) * [ Content Explore content ](javascript:;) ## Explore content * [ Research articles ](https://www.nature.com/nrclinonc/research-articles) * [ Reviews & Analysis ](https://www.nature.com/nrclinonc/reviews-and-analysis) * [ News & Comment ](https://www.nature.com/nrclinonc/news-and-comment) * [ Current issue ](https://www.nature.com/nrclinonc/current-issue) * [ Collections ](https://www.nature.com/nrclinonc/collections) * [Follow us on Facebook ](https://www.facebook.com/NatureReviews) * [Follow us on X ](https://twitter.com/NatRevClinOncol) * [ Subscribe ](https://www.nature.com/nrclinonc/subscribe) * [Sign up for alerts ](https://journal-alerts.springernature.com/subscribe?journal_id=41571) * [ RSS feed ](https://www.nature.com/nrclinonc.rss) * [ About the journal ](javascript:;) ## About the journal * [ Aims & Scope ](https://www.nature.com/nrclinonc/aims) * [ Journal Information ](https://www.nature.com/nrclinonc/journal-information) * [ Editors ](https://www.nature.com/nrclinonc/editors) * [ Editorial policies ](https://www.nature.com/nrclinonc/editorial-policies) * [ Reviews Cross-Journal Editorial Team ](https://www.nature.com/nrclinonc/reviews-cross-journal-editorial-team) * [ Journal Credits ](https://www.nature.com/nrclinonc/journal-credits) * [ Editorial input and checks ](https://www.nature.com/nrclinonc/editorial-input-and-checks) * [ Editorial Values Statement ](https://www.nature.com/nrclinonc/editorial-values-statement) * [ Journal Metrics ](https://www.nature.com/nrclinonc/journal-impact) * [ Publishing model ](https://www.nature.com/nrclinonc/publishing-model) * [ Conferences ](https://www.nature.com/nrclinonc/conferences) * [ Web Feeds ](https://www.nature.com/nrclinonc/web-feeds) * [ Contact ](https://www.nature.com/nrclinonc/contact) * [ Publish with us ](javascript:;) ## Publish with us * [ For Authors ](https://www.nature.com/nrclinonc/for-authors) * [ For Referees ](https://www.nature.com/nrclinonc/for-referees) * [Submit manuscript ](https://mts-nrclinonc.nature.com/cgi-bin/main.plex) * [ Subscribe ](https://www.nature.com/nrclinonc/subscribe) * [ Sign up for alerts ](https://journal-alerts.springernature.com/subscribe?journal_id=41571) * [ RSS feed ](https://www.nature.com/nrclinonc.rss) 1. [nature](https://www.nature.com/) 2. [nature reviews clinical oncology](https://www.nature.com/nrclinonc) 3. [comments](https://www.nature.com/nrclinonc/articles?type=comment) 4. article * Comment * Published: 28 October 2026 # Problematic control arms in National Cancer Institute myeloma trials * [Jacqueline Kunesh](https://www.nature.com/articles/s41571-026-01221-3#auth-Jacqueline-Kunesh-Aff1)[1](https://www.nature.com/articles/s41571-026-01221-3#Aff1) & * [Ghulam Rehman Mohyuddin](https://www.nature.com/articles/s41571-026-01221-3#auth-Ghulam_Rehman-Mohyuddin-Aff2) [ORCID: orcid.org/0000-0001-6464-783X](https://orcid.org/0000-0001-6464-783X)[2](https://www.nature.com/articles/s41571-026-01221-3#Aff2) [_Nature Reviews Clinical Oncology_](https://www.nature.com/nrclinonc) (2026) [Cite this article](https://www.nature.com/articles/s41571-026-01221-3#citeas) Save article [ View saved research ](https://www.nature.com/saved-research) Three of five National Cancer Institute-sponsored randomized trials that are currently enrolling patients with multiple myeloma have control arms that no longer reflect the standard of care, despite two of these trials being activated in 2026. Comparators in federally sponsored trials need reassessment and, if necessary, updating to reflect changes in clinical practice before and during enrolment. This is a preview of subscription content, [access via your institution](https://wayf.springernature.com?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41571-026-01221-3) ## Access options [ Access through your institution ](https://wayf.springernature.com?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41571-026-01221-3) Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription 32.70 € / 30 days cancel any time [Learn more](https://shop.nature.com/products/plus/?region=ROW) Subscribe to this journal Receive 12 print issues and online access 176.64 € per year only 14.72 € per issue [Learn more](https://www.nature.com/nrclinonc/subscribe) Buy this article * Purchase on SpringerLink * Instant access to the full article PDF. 39,95 € Prices may be subject to local taxes which are calculated during checkout ### Additional access options: * [Log in](https://idp.nature.com/auth/personal/springernature?client_id=grover&redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41571-026-01221-3) * [Learn about institutional subscriptions](https://www.springernature.com/gp/librarians/licensing/license-options) * [Read our FAQs](https://support.nature.com/en/support/home) * [Contact customer support](https://www.springernature.com/gp/contact) ## References 1. Mohyuddin, G. R. et al. Quality of control groups in randomised trials of multiple myeloma enrolling in the USA: a systematic review. _Lancet Haematol._ **8** , e299–e304 (2021). [Article](https://doi.org/10.1016%2FS2352-3026%2821%2900024-7) [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3sXis1yjsr8%3D) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=33770485) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Quality%20of%20control%20groups%20in%20randomised%20trials%20of%20multiple%20myeloma%20enrolling%20in%20the%20USA%3A%20a%20systematic%20review&journal=Lancet%20Haematol.&doi=10.1016%2FS2352-3026%2821%2900024-7&volume=8&pages=e299-e304&publication_year=2021&author=Mohyuddin%2CGR) 2. Ding, K. L., Kunesh, J., Neupane, K. & Mohyuddin, G. R. Improving control arms in 2026 US myeloma trials. _Blood Adv._ **10** , 4423–4426 (2026). [Article](https://doi.org/10.1182%2Fbloodadvances.2026020329) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=41995759) [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC13315678) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Improving%20control%20arms%20in%202026%20US%20myeloma%20trials&journal=Blood%20Adv.&doi=10.1182%2Fbloodadvances.2026020329&volume=10&pages=4423-4426&publication_year=2026&author=Ding%2CKL&author=Kunesh%2CJ&author=Neupane%2CK&author=Mohyuddin%2CGR) 3. Rossi, A. et al. Analysis of the adequacy of control arms in oncology randomised clinical trials published between 2017 and 2021: a meta-research study. _Eur. J. Cancer_ **189** , 112920 (2023). [Article](https://doi.org/10.1016%2Fj.ejca.2023.05.008) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=37277262) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Analysis%20of%20the%20adequacy%20of%20control%20arms%20in%20oncology%20randomised%20clinical%20trials%20published%20between%202017%20and%202021%3A%20a%20meta-research%20study&journal=Eur.%20J.%20Cancer&doi=10.1016%2Fj.ejca.2023.05.008&volume=189&publication_year=2023&author=Rossi%2CA) 4. Lieu, C. H. & Sanoff, H. K. Ensuring the future of cooperative group cancer clinical trials: a call for comprehensive support and prioritization. _JCO Oncol. Pract._ (2026). [Article](https://doi.org/10.1200%2FOP-25-00927) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=41529232) [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12802855) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Ensuring%20the%20future%20of%20cooperative%20group%20cancer%20clinical%20trials%3A%20a%20call%20for%20comprehensive%20support%20and%20prioritization&journal=JCO%20Oncol.%20Pract.&doi=10.1200%2FOP-25-00927&publication_year=2026&author=Lieu%2CCH&author=Sanoff%2CHK) 5. Sonneveld, P. et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. _N. Engl. J. Med._ **390** , 301–313 (2024). [Article](https://doi.org/10.1056%2FNEJMoa2312054) [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB2cXitFSmsLY%3D) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=38084760) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Daratumumab%2C%20bortezomib%2C%20lenalidomide%2C%20and%20dexamethasone%20for%20multiple%20myeloma&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJMoa2312054&volume=390&pages=301-313&publication_year=2024&author=Sonneveld%2CP) 6. Usmani, S. Z. et al. Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial. _Nat. Med._ **31** , 1195–1202 (2025). [Article](https://doi.org/10.1038%2Fs41591-024-03485-7) [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB2MXjtVKjtL4%3D) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=39910273) [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12003169) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Daratumumab%20plus%20bortezomib%2C%20lenalidomide%20and%20dexamethasone%20for%20transplant-ineligible%20or%20transplant-deferred%20newly%20diagnosed%20multiple%20myeloma%3A%20the%20randomized%20phase%203%20CEPHEUS%20trial&journal=Nat.%20Med.&doi=10.1038%2Fs41591-024-03485-7&volume=31&pages=1195-1202&publication_year=2025&author=Usmani%2CSZ) 7. Kumar, S. K. et al. Multiple myeloma, version 5.2026, NCCN clinical practice guidelines in oncology. _J. Natl Compr. Canc. Netw._ **24** , e260001 (2026). [Article](https://doi.org/10.6004%2Fjnccn.2026.0001) [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB28XitlOqt7%2FK) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=41671464) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Multiple%20myeloma%2C%20version%205.2026%2C%20NCCN%20clinical%20practice%20guidelines%20in%20oncology&journal=J.%20Natl%20Compr.%20Canc.%20Netw.&doi=10.6004%2Fjnccn.2026.0001&volume=24&publication_year=2026&author=Kumar%2CSK) 8. Costa, L. J. et al. Teclistamab plus daratumumab in relapsed or refractory multiple myeloma. _N. Engl. J. Med._ **394** , 739–752 (2025). [Article](https://doi.org/10.1056%2FNEJMoa2514663) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=41363801) [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC13218738) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Teclistamab%20plus%20daratumumab%20in%20relapsed%20or%20refractory%20multiple%20myeloma&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJMoa2514663&volume=394&pages=739-752&publication_year=2025&author=Costa%2CLJ) 9. Einsele, H. et al. Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial. _Lancet Oncol._ **27** , 254–268 (2026). [Article](https://doi.org/10.1016%2FS1470-2045%2825%2900653-9) [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB28Xht1KrsLY%3D) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=41519141) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Cilta-cel%20in%20lenalidomide-refractory%20multiple%20myeloma%20%28CARTITUDE-4%29%3A%20an%20updated%20analysis%20including%20overall%20survival%20from%20an%20open-label%2C%20multicentre%2C%20randomised%2C%20phase%203%20trial&journal=Lancet%20Oncol.&doi=10.1016%2FS1470-2045%2825%2900653-9&volume=27&pages=254-268&publication_year=2026&author=Einsele%2CH) 10. Kumar, S. Amended trial: Shaji Kumar gives an update on the EAA181/EQUATE study for patients with newly diagnosed multiple myeloma. _ECOG-ACRIN_ (2026). [Download references](https://citation-needed.springer.com/v2/references/10.1038/s41571-026-01221-3?format=refman&flavour=references) ## Acknowledgements All data analysed in this study are publicly available through ClinicalTrials.gov. The study dataset and analysis criteria are available via e-mail from the corresponding author on request. ## Author information ### Authors and Affiliations 1. University of Arizona College of Medicine–Phoenix, Phoenix, AZ, USA Jacqueline Kunesh 2. Division of Hematology and Hematological Malignancies, The University of Utah, Salt Lake City, UT, USA Ghulam Rehman Mohyuddin Authors 1. Jacqueline Kunesh [View author publications](https://www.nature.com/search?author=Jacqueline%20Kunesh) Search author on:[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Jacqueline%20Kunesh)[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Jacqueline%20Kunesh%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en) 2. Ghulam Rehman Mohyuddin [View author publications](https://www.nature.com/search?author=Ghulam%20Rehman%20Mohyuddin) Search author on:[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Ghulam%20Rehman%20Mohyuddin)[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Ghulam%20Rehman%20Mohyuddin%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en) ### Corresponding author Correspondence to Ghulam Rehman Mohyuddin. ## Ethics declarations ### Competing interests G.R.M’s institution has received research funding from Janssen and Sanofi. J.K. declares no competing interests. ## Rights and permissions [Reprints and permissions](https://s100.copyright.com/AppDispatchServlet?title=Problematic%20control%20arms%20in%20National%20Cancer%20Institute%20myeloma%20trials&author=Jacqueline%20Kunesh%20et%20al&contentID=10.1038%2Fs41571-026-01221-3&copyright=Springer%20Nature%20Limited&publication=1759-4774&publicationDate=2026-10-28&publisherName=SpringerNature&orderBeanReset=true) ## About this article [![Check for updates. Verify currency and authenticity via CrossMark](https://www.nature.com/articles/s41571-026-01221-3)](https://crossmark.crossref.org/dialog/?doi=10.1038/s41571-026-01221-3) ### Cite this article Kunesh, J., Mohyuddin, G.R. Problematic control arms in National Cancer Institute myeloma trials. _Nat Rev Clin Oncol_ (2026). https://doi.org/10.1038/s41571-026-01221-3 [Download citation](https://citation-needed.springer.com/v2/references/10.1038/s41571-026-01221-3?format=refman&flavour=citation) * Published: 28 October 2026 * Version of record: 28 October 2026 * DOI: https://doi.org/10.1038/s41571-026-01221-3 ### Share this article Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy shareable link to clipboard Provided by the Springer Nature SharedIt content-sharing initiative ### Subjects * [Careers](https://www.nature.com/subjects/careers) * [Myeloma](https://www.nature.com/subjects/myeloma) [ Access through your institution ](https://wayf.springernature.com?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41571-026-01221-3) [ Buy or subscribe ](https://www.nature.com/articles/s41571-026-01221-3#access-options) * Sections * References * [References](https://www.nature.com/articles/s41571-026-01221-3#Bib1) * [Acknowledgements](https://www.nature.com/articles/s41571-026-01221-3#Ack1) * [Author information](https://www.nature.com/articles/s41571-026-01221-3#author-information) * [Ethics declarations](https://www.nature.com/articles/s41571-026-01221-3#ethics) * [Rights and permissions](https://www.nature.com/articles/s41571-026-01221-3#rightslink) * [About this article](https://www.nature.com/articles/s41571-026-01221-3#article-info) Advertisement 1. Mohyuddin, G. R. et al. Quality of control groups in randomised trials of multiple myeloma enrolling in the USA: a systematic review. _Lancet Haematol._ **8** , e299–e304 (2021). [Article](https://doi.org/10.1016%2FS2352-3026%2821%2900024-7) [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3sXis1yjsr8%3D) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=33770485) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Quality%20of%20control%20groups%20in%20randomised%20trials%20of%20multiple%20myeloma%20enrolling%20in%20the%20USA%3A%20a%20systematic%20review&journal=Lancet%20Haematol.&doi=10.1016%2FS2352-3026%2821%2900024-7&volume=8&pages=e299-e304&publication_year=2021&author=Mohyuddin%2CGR) 2. Ding, K. L., Kunesh, J., Neupane, K. & Mohyuddin, G. R. Improving control arms in 2026 US myeloma trials. _Blood Adv._ **10** , 4423–4426 (2026). [Article](https://doi.org/10.1182%2Fbloodadvances.2026020329) [PubMed](http://www.ncbi.nlm.nih.gov/entr
## Related Clinical Research

- [Glucocorticoid signaling and microRNA networks in acute lymphoblastic leukemia: GAO078 model findi](https://medichelpline.com/clinical-feed/pubmed-43059396.md) (DOI: 10.3892/ijo.2026.5963)
- [PLOS One Editorial Note: Concerns Raised Over Dexamethasone Study Figures](https://medichelpline.com/clinical-feed/plos-one-20-editorial-note-dexamethasone-alleviates-tumor-associated-brain-damage-and.md)
- [Teclistamab in high-risk smouldering multiple myeloma: assessing whether deep responses can preven](https://medichelpline.com/clinical-feed/nature-reviews-clinical-oncology-0-t-cell-redirection-in-high-risk-smouldering-multiple-myeloma-can-deep-responses.md)
- [Aquaporin-4 (AQP4) Modulates Edema, Astrocyte State, and Immune Remodeling in Glioblastoma](https://medichelpline.com/clinical-feed/biorxiv-7-aquaporin-4-regulates-edema-sustains-astrocyte-differentiation-and-constrains.md)
- [Angioimmunoblastic T‑cell Lymphoma Complicated by Secondary HLH Initially Misdiagnosed as Classica](https://medichelpline.com/clinical-feed/pubmed-42826277.md) (DOI: 10.1097/MD.0000000000050979)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.